An Alternative to Biopsy: Improved CTC Collection Method

​ Researchers at the University of Michigan have developed a prototype of a wearable device that can continuously collect circulating tumor cells (CTCs) directly from a patient's bloodstream. The investigators hope that this device, which has thus far proven successful in canine models, could ultimately be used as an alternative to biopsies. Circulating tumor cells, which circulate through lymphatic channels and blood after they are shed from the primary tumor, are the basis for cancer metastase...
Continue reading

Castration-Resistant Prostate Cancer: New Developments, New Challenges With Alicia Morgans, MD, MPH

​ Prostate cancer is the most common tumor type in men in the United States. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process that lacks effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, with a median overall survival that remains less than two years. In this interview with i3 Health, Alicia K. Morgans, MD, MPH, Associate Professor of Medicine at Northwestern University Feinberg School of Medicine, ...
Continue reading

EN2 Secretions: Potential New Prostate Cancer Target

Researchers discovered that the transcription factor protein Engrailed-2 (EN2), which forms boundaries and guides neurons in development, also plays a role in cancer: tumors secrete EN2, which is then taken up by the surrounding normal cells, preventing immune invasion. Lead researcher Richard Morgan, PhD, Professor of Molecular Oncology at the University of Bradford, remarked, "For tumors to survive, grow bigger, and spread, they need to control the behavior of cancer cells and the normal cells...
Continue reading

LumosVar: Technology Shapes Cancer Patients’ Treatment Path

Researchers at the Translational Genomics Research Institute (TGen) have developed a computer program called LumosVar that "lights up" oncogenic mutations in tumor samples, allowing health care providers to gain insight regarding how best to treat patients. By collecting and analyzing these samples, LumosVar can help oncologists to determine a patient's response to treatment. The lead author of the study, Rebecca Halperin, PhD, Research Assistant Professor in the Quantitative Medicine & Syst...
Continue reading

Adding Docetaxel to Androgen Suppression and Radiotherapy in High-Risk Prostate Cancer: An Interview With Seth A. Rosenthal, MD, FACR, FASTRO

Of the 20% of patients with prostate cancer who have high-risk disease, around 30% to 40% experience a relapse following initial treatment. Less than 50% of these patients are cured. A phase 3 clinical trial, the NRG Oncology trial NRG-RTOG 0521, reports a way to improve survival for patients with nonmetastatic, high-risk prostate cancer: adding docetaxel to a standard regimen consisting of radiotherapy (RT) and long-term androgen suppression (AS) . In this interview with i3 Health, Seth A. Rose...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.